WO2005054281A2 - Proteína nmb1125 y su uso en formulaciones farmaceuticas - Google Patents
Proteína nmb1125 y su uso en formulaciones farmaceuticas Download PDFInfo
- Publication number
- WO2005054281A2 WO2005054281A2 PCT/CU2004/000015 CU2004000015W WO2005054281A2 WO 2005054281 A2 WO2005054281 A2 WO 2005054281A2 CU 2004000015 W CU2004000015 W CU 2004000015W WO 2005054281 A2 WO2005054281 A2 WO 2005054281A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- nmb1125
- pharmaceutical formulation
- formulation according
- sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 150
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 120
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 26
- 229960005486 vaccine Drugs 0.000 claims abstract description 49
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 38
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 102000036639 antigens Human genes 0.000 claims abstract description 35
- 108091007433 antigens Proteins 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 238000009472 formulation Methods 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 230000001681 protective effect Effects 0.000 claims abstract description 9
- 230000001580 bacterial effect Effects 0.000 claims abstract description 3
- 230000004044 response Effects 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 208000037941 meningococcal disease Diseases 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 150000004676 glycans Chemical class 0.000 claims description 11
- 241000588653 Neisseria Species 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 5
- 239000000306 component Substances 0.000 claims 3
- 235000003869 genetically modified organism Nutrition 0.000 claims 2
- 239000005426 pharmaceutical component Substances 0.000 claims 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000002434 immunopotentiative effect Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 19
- 239000012528 membrane Substances 0.000 abstract description 16
- 230000028993 immune response Effects 0.000 abstract description 12
- 230000005847 immunogenicity Effects 0.000 abstract description 10
- 241000282414 Homo sapiens Species 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 244000052769 pathogen Species 0.000 abstract description 3
- 238000001228 spectrum Methods 0.000 abstract description 3
- 238000012163 sequencing technique Methods 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract description 2
- 239000003899 bactericide agent Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 101
- 230000003053 immunization Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- 238000002649 immunization Methods 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 101710116435 Outer membrane protein Proteins 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 230000009260 cross reactivity Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 208000034762 Meningococcal Infections Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 241000831652 Salinivibrio sharmensis Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940125575 vaccine candidate Drugs 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940023143 protein vaccine Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 241000701533 Escherichia virus T4 Species 0.000 description 4
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940124731 meningococcal vaccine Drugs 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000000782 polymeric membrane extraction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000012268 genome sequencing Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 101000846901 Drosophila melanogaster Fat-body protein 1 Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 101710167887 Major outer membrane protein P.IA Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010027249 Meningitis meningococcal Diseases 0.000 description 2
- 201000010924 Meningococcal meningitis Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000012768 mass vaccination Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 1
- KMGOBAQSCKTBGD-DLOVCJGASA-N Ala-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CN=CN1 KMGOBAQSCKTBGD-DLOVCJGASA-N 0.000 description 1
- YNDLOUMBVDVALC-ZLUOBGJFSA-N Asn-Ala-Ala Chemical compound C[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC(=O)N)N YNDLOUMBVDVALC-ZLUOBGJFSA-N 0.000 description 1
- XVVOVPFMILMHPX-ZLUOBGJFSA-N Asn-Asp-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XVVOVPFMILMHPX-ZLUOBGJFSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 238000000846 Bartlett's test Methods 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 1
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 1
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 1
- AQNYKMCFCCZEEL-JYJNAYRXSA-N Glu-Lys-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AQNYKMCFCCZEEL-JYJNAYRXSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- FKJQNJCQTKUBCD-XPUUQOCRSA-N Gly-Ala-His Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O FKJQNJCQTKUBCD-XPUUQOCRSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 1
- FHQRLHFYVZAQHU-IUCAKERBSA-N Gly-Lys-Gln Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O FHQRLHFYVZAQHU-IUCAKERBSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 1
- YIRIDPUGZKHMHT-ACRUOGEOSA-N Leu-Tyr-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YIRIDPUGZKHMHT-ACRUOGEOSA-N 0.000 description 1
- 108010062166 Lys-Asn-Asp Proteins 0.000 description 1
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 description 1
- KJIXWRWPOCKYLD-IHRRRGAJSA-N Lys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N KJIXWRWPOCKYLD-IHRRRGAJSA-N 0.000 description 1
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710107904 NADH-ubiquinone oxidoreductase subunit 9 Proteins 0.000 description 1
- 241000529648 Neisseria meningitidis MC58 Species 0.000 description 1
- 241000529650 Neisseria meningitidis Z2491 Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 101150093941 PORA gene Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- XWBJLKDCHJVKAK-KKUMJFAQSA-N Phe-Arg-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N XWBJLKDCHJVKAK-KKUMJFAQSA-N 0.000 description 1
- KYYMILWEGJYPQZ-IHRRRGAJSA-N Phe-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KYYMILWEGJYPQZ-IHRRRGAJSA-N 0.000 description 1
- KPEIBEPEUAZWNS-ULQDDVLXSA-N Phe-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KPEIBEPEUAZWNS-ULQDDVLXSA-N 0.000 description 1
- OAOLATANIHTNCZ-IHRRRGAJSA-N Phe-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N OAOLATANIHTNCZ-IHRRRGAJSA-N 0.000 description 1
- YUPRIZTWANWWHK-DZKIICNBSA-N Phe-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N YUPRIZTWANWWHK-DZKIICNBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710132845 Protein P1 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- MUARUIBTKQJKFY-WHFBIAKZSA-N Ser-Gly-Asp Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MUARUIBTKQJKFY-WHFBIAKZSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- HJOSVGCWOTYJFG-WDCWCFNPSA-N Thr-Glu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O HJOSVGCWOTYJFG-WDCWCFNPSA-N 0.000 description 1
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 1
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- XJPXTYLVMUZGNW-IHRRRGAJSA-N Tyr-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O XJPXTYLVMUZGNW-IHRRRGAJSA-N 0.000 description 1
- 101710159648 Uncharacterized protein Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001948 anti-meningococcal effect Effects 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010075431 glycyl-alanyl-phenylalanine Proteins 0.000 description 1
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention is related to the branch of medicine, particularly with the development of new vaccine formulations, of preventive or therapeutic application, which allow an increase in the quality of the immune response against vaccine antigens against diseases of diverse origin.
- Neisseria meningitidis a Gram negative diplococcus whose sole host is man, is the causative agent of meningococcal meningitis.
- this bacterium is in an asymptomatic carrier state in the population, this being the most common route for its microbiological isolation.
- meningococcal meningitis In the world, children under 2 years of age are the population most susceptible to meningococcal meningitis, however, young adolescents and the population of older adults can also be affected. Untreated meningococcal disease is fatal in most affected individuals, and vaccination could prevent this situation by avoiding even such early stages as bacterial colonization.
- capsular polysaccharides have been studied and evaluated as vaccine candidates.
- a tetravalent, polysaccharide-based vaccine that confers protection against serogroups A, C, Y, and W-135 has been licensed in the United States.
- the antibodies that are generated after Vaccination are serogroup-specific (Rosenstein N. et al. 2001. Menningococcal disease. N. Engl. J. Med, 344, 1378-1388).
- Serogroup B unlike the rest, continues to be a major cause of endemic and epidemic meningococcal disease, largely due to the absence of effective vaccines against it. It has been seen that serogroup B polysaccharide has a low immunogenicity, in addition to the theoretical risk that vaccines based on this compound could develop immunotolerance and induce autoimmunity given its structural homology with oligosaccharide chains present in human fetal structures (Finne J. ef al. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissue. J. Immunol, 138: 4402-4407).
- the vaccine produced by the Finlay Institute in Cuba (commercially known as VA-MENGOC-BC ® ) is produced from strain B: 4: P1.19,15 and is composed of a PME preparation of said strain and isolated capsular polysaccharide of serogroup C, adsorbed to aluminum hydroxide (Sierra GV et al. 1991. Vaccine against group B Neisseria meningitidis: protection tria! and mass vaccination results in Cuba. NIPH Ann Dis. 14 (2): 195-210).
- This vaccine contributed to a rapid decline in the epidemic in Cuba (Rodr ⁇ guez AP, et al. The epidemiological impact of antimeningococcal B vaccination in Cuba. 1999. Mem Inst Oswaldo Cruz. 94 (4): 433 ⁇ 10).
- VME vaccines appear to be effective in the presentation of PME, arranged in their natural conformation, to allow the generation of bactericidal antibodies, at least in adolescents and adults. The antibody responses generated increased the opsonophagocytosis of the meningococcus.
- vaccines for example: PME content, LPS content and the presence or absence of adjuvant
- PME content, LPS content and the presence or absence of adjuvant has a significant impact on immunogenicity and there are large differences from one producer to another according to the strain and / or the methodology used
- VME vaccines have been more used than any other serogroup B vaccine and are useful in the context of disease outbreaks caused by a single type of strain.
- P1 protein is an antigen with a significant level of variability, which seems to undergo continuous variation between and during outbreaks (Jelfs J, ef al. 2000. Sequence Variation in the porA Gene of a Clone of Neisseria meningitidis during Epidemic Spread. Clin Diagn Lab Immunol.
- VME vaccine was developed in the Netherlands, (RIVM) containing P1 of six different pathogenic isolates (Van Der Ley P and Poolman JT. 1992. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein Infect Immun. 60 (8): 3156-61, Claassen I, et al. 1996.
- VME external membrane vesicle
- TbpA and B class 5 proteins
- TbpA and B class 5 proteins
- FbpA and FetA iron-regulated proteins
- TbpB is part of the transferrin binding complex, together with TbpA.
- TbpA has a more important role in iron binding (Painter M, et al. 1998. Analysis of TbpA and TbpB functionality in defective mutants of Neisseria meningitidis. J Med Microbiol 47 (9): 757-60) and it is a more effective immunogen than TbpB.
- NspA The presence of NspA was detected by ELISA in 99.2% of the fesiated strains belonging to serogroups from A to C, using monoclonal antibodies (Martin D, et al. 1997. Highly conserveed Neisseria meningitidis Sur ⁇ ace Protein Confers Protection against Experimental Infection J Exp Med 185 (7): 1173-83). These monoclonal antibodies have been shown to have bactericidal activity against numerous strains of meningococcus and are capable of reducing the bacteraemia caused by this microorganism in a murine model (Cadieux N, et al. 1999.
- Vaccines consisting of a single protein have been used for decades and have generally shown good stability, but it can vary if the presentation of proteins in the form of vesicles is required to ensure that the antigens remain attached to the membrane.
- the immunogenicity and reactogenicity of VME can vary with alterations in the amount of proteins and LPS removed during the purification process.
- the construction of synthetic liposomal vesicles allows the optimization and standardization of these vaccines (Christodoulides M, et al. 1998.
- Intramuscular injection of the meningococcal vaccine has been the route used that allows the production of systemic immunoglobulin G (IgG), although the production of secretory IgA is important, since during meningococcal infection the invasion of the host occurs via the nasal epithelium.
- Genome sequencing of N. meningitidis Genome sequencing of MC58 (a strain of serogroup B meningococcus) (Tettelin H, et al. 2000. Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58. Science 287 (5459): 1809-15172) and Z2491 (a serogroup A strain) (Parkhill J, et al. 2000.
- Vaccine formulations using some of these proteins combined with adjuvants induced significant titers of bactericidal antibodies against the homologous strain (MC58), but none of them was as high as those induced by a VME vaccine of this same strain (Giuliani MM, et to 2000. Proceedings 12th IPNC. p. 22).
- MC58 homologous strain
- combinations of these proteins are more immunogenic than each protein separately (Santini L. et al. 2000. Proceedings 12th I PNC. P. 25).
- the numerous ORFs excluded in this work perhaps due to the lack of protein expression or due to changes in immunological properties, need further investigation.
- the components of a vaccine should be selected based on the contribution of the antigens in the pathogenesis of N. meningitidis.
- the antigens alone they can be effective vaccine candidates, or alternatively, the attenuated mutants can be considered members of a vaccine. In this sense, the use of candidates whose sequence is highly conserved even among different genera of pathogenic microorganisms, could be a solution to the effects produced by them in case they generate a convenient response from the immune system.
- the technical objective pursued with this invention is precisely the development of formulations capable of raising and / or expanding the body's immune response against several pathogens or against a broad spectrum of varieties thereof, these pathogens being parasitic, bacterial, viral. , cancerous or other.
- the use of the NMB1125 protein is reported for the first time as a component of a vaccine formulation of a therapeutic or preventive nature against meningococcal disease or any infection caused by a member of the Neisseria genus.
- the novel nature of this invention resides in the previously unreported use of the NMB1125 protein in formulations with new properties, capable of inducing a systemic and mucosal immune response of a broad protective spectrum, given the conserved nature of this protein in different isolates of Neisseria meningitidis and Neisser ⁇ a gonorrhoeae.
- Figure 1 Vector pM100 used in the cloning and expression of the NMB1125 protein.
- pTrip tryptophan promoter
- N-term P64k N-terminal fragment of the P64k
- T4 Terminator transcription terminator of bacteriophage T4.
- Figure 3 Analysis by SDS-PAGE of the fractions obtained in the cell rupture; lane 1, total cells; lane 2, precipitate of rupture; lane 3, rupture supernatant.
- Figure 4. Analysis by SDS-PAGE of the NMB1125 protein purification process from the rupture supernatant; lane 1, resulting protein; lane 2, a contaminant protein of lower molecular weight that migrates in another chromatographic peak; Lane 3, sample before applying.
- FIG. 1 Western blotting recognition of the NMB1125 protein present in the N. meningitidis PMEs using sera from mice immunized with the recombinant protein: The arrow indicates the band corresponding to the immunoidentified NMB1125 protein.
- Figure 7 Response of IgA antibodies against the recombinant protein NMB1125, at the mucosal level, in mice immunized with the antigen intranasally. The results are expressed as the inverse of the title, calculated as that dilution of the sample where the optical density of the preimmune sample is doubled.
- A Response of IgA antibodies in saliva.
- B Response of IgA antibodies in lung washes
- Figure 8 Results of the search for similarity between the gene that codes for the NMB1125 protein (“query”) and the annotated sequences of the genomes of different serogroups of Neisseria meningitidis (“Sbjct”) using the BLAST program.
- FIG. 9 Recognition of the NMB1125 protein in different strains of N. meningitidis, for sera produced against the recombinant antigen.
- the graph only shows the values obtained when immunized with the semi-purified protein intraperitoneally, although in the rest of the cases a similar behavior was observed.
- the results were expressed as the inverse of the title, calculated as the dilution of the serum where the optical density of the preimmune serum is doubled.
- Figure 10 Comparison between sera obtained by immunizing with the protein obtained by two procedures, administered intraperitoneally, in the passive protection experiment against meningococcal infection, in the infant rat model.
- Figure 11 Recognition of the NMB1125 protein, and a panel of unrelated antigens, by the mAbs generated (mAbs H8 / 92, 3H2764 and 7D2 / 15).
- P64k subunit E3 of the enzyme pyruvate dehydrogenase from Neisseria meningitidis] T.T, tetanus toxoid;
- HBsAg surface antigen of the Hepatitis B virus.
- Protein identification based on ESI-MS spectra was performed using the ProFound program (Zhang W and Chait BT. 2000. ProFound: an expert system for protein identification using mass spectrometric peptide mapping information. Anal Chem 72: 2482-2489. Http : //prowl.rockefeller.edu/cgi-bin/ProFound).
- Protein identification based on MS / MS spectra was performed through the MASCOT program (Perkins DN, et al. 1999. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20: 3551-3567. Http : //www.matrixscience.com/). Search parameters included cysteine modification as well as possible oxidations and deamidations. From the analysis of the data obtained from the identification of the proteins present in preparations of outer membrane vesicles, it was selected to evaluate as a possible vaccine candidate for the NMB1125 protein from which it was identified by mass peptide 1 spectrometry.
- Example 3 Cloning and expression of the NMB1125 gene, coding for the NMB1125 protein of N. meningitidis in Escher ⁇ chia coli.
- the vector pM-100 was used, which vector allows cloning using different restriction enzymes, and obtaining high levels of heterologous protein expression in the form of cytoplasmic inclusion bodies in E. coli .
- the vector pM-100 ( Figure 1) has the following main elements: tryptophan promoter, sequence corresponding to the N-terminal stabilizing segment of the P64k antigen of N.
- meningitldis strain B 4: P1.19.15 coding for 47 aa, sequence corresponding to the transcription terminator of the bacteriophage T4 and sequence corresponding to the gene that confers ampicillin resistance as a selection marker.
- an oligonucleotide pair (7738 and 7739) was designed to amplify the segment of said gene without the sequence encoding the signal peptide, using the genomic DNA of strain B: 4: P1.19,15.
- the sequencing of the cloned NMB1125 gene segment was performed using the automatic sequencer ALFexpressIl (Thermo Sequenase TM Cy TM 5 Dye Terminator Kit, Amersham Biosciences) and oligonucleotides 1573 (No. Sequence identification: 8) and 6795 (No. Sequence identification : 9), which hybridize in the sequence corresponding to the stabilizing segment of the P64k and in the transcription terminator of the bacteriophage T4, respectively.
- the plasmid obtained was named pM-238 for later use.
- the E. coli strain GC 366 was transformed by chemical method with plasmid pM-238 ( Figure 2).
- the expression experiment was performed in minimal M9 saline medium (Miller JH. 1972. Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, NEW York, USA) supplemented with 1% glycerol, 1% hydrolyzed casein, CaCI 2 0.1 mM, 1mM MgSO 4 and 50 ug / mL ampicillin
- the cultures were incubated for 12 h at 37 ° C at 250 rpm. After this time they were centrifuged and the cell precipitate ruptured by ultrasonic disruption (IKA LABORTECHNIK).
- the fraction containing the protein was then dialyzed to Buffer A (25mM Tris-hydroxymethyl amino methane) and the NMB1125 protein was purified by ion exchange chromatography using a 5/5 monoQ column (Amersham Biosciences) with a 0 to 100% NaCI gradient in 1h [BufferA as equilibrium buffer and BufferB (BufferA + 1M NaCI) to create the gradient], which was finally obtained with 80% purity as shown in Figure 4.
- Buffer A 25mM Tris-hydroxymethyl amino methane
- BufferB BufferA + 1M NaCI
- mice In which the same protein obtained by two different methods was administered. The first was to extract the band from a polyacrylamide gel (Castellanos L, et al. 1996. A procedure for protein elution from, reverse-stained poiyarcylamide gels applicable at the low picomole level: An alternative route to the preparation of low abundance proteins for microanalysis Electrophoresis 17: 1564-1572) and the second one was referred to in Example 3, whose product was denoted as semi-purified protein. With these preparations, female Balb / c mice, 8 to 10 weeks old, were immunized, which were divided into 4 groups of 8 mice each.
- Table 1 describes the composition of the groups: Tablal: Groups of Balb / C mice used for immunization
- Antibody titers (IgG) against the recombinant protein and the homologous protein present in the bacteria were determined by an ELISA type assay, in sera obtained after the third inoculation.
- the antibody titers of each animal against the recombinant protein are shown in Figure 5. After the second inoculation, antibody levels are detected, although they were higher after the third inoculation.
- Immunological identification was also performed by Western blotting, detecting the recognition of the band corresponding to the protein.
- Example 5 Characterization of the gene sequence coding for the NMB1125 protein in different strains of N. meningitidis.
- Figure 8 shows the results of the sequence comparison for those sequences that produce a significant alignment in each of the genomes analyzed. These sequences have 100% or identity in serogroups A and B, and 99% identity in serogroup C, with the gene sequence coding for the NMB1125 protein obtained (No. Sequence identification: 3). Additionally, the nucleotide sequence of the gene in question was determined for 3 Cuban isolates (No. Sequence identification: 5-7) belonging to serogroup B (B: 4: P1.19,15) and sequence alignment was performed using the program ClustalX (http://www.ebi.ac.uk/clustalw/). The results of the alignment show that there is a great conservation in the nucleotide sequence of the NMB1125 gene among the different strains analyzed.
- NMB1125 protein as a vaccine candidate, taking into account the high degree of similarity between the aforementioned sequences, would allow to generate an effective and broad-spectrum immune response (product of cross-reactivity), against meningococcal disease.
- Example 7 Protection induced by murine sera generated against the NMB1125 protein, against homologous and heterologous strains, in the infant rat model
- the immunization scheme was performed in Balb / c mice (H-2 d , female sex, 5-6 weeks) and had a total of 4 doses distributed as follows: on days 0, 15 and 30 of the 10 ⁇ g scheme of the NMB1125 antigen per mouse (total volume 100 ⁇ l), administered subcutaneously, emulsified the first dose with Freund's complete adjuvant, and the remaining doses with Freund's Incomplete Adjuvant; on day 50, 10 ⁇ g of the antigen per mouse in phosphate buffer solution (140 mM NaCI, 270 mM KCI, 1.5 mM KH 2 PO 4 , 6.5 mM Na 2 HPO x 2H 2 O, pH 7.2) intraperitoneally. Extractions were performed on days 0 and 45 of the scheme.
- the splenocytes of the best-titted animal evaluated by an indirect ELISA using the NMB1125 protein (Example 3) in the coating, were fused with the myeloma X63 Ag8 653 cells and the resulting hybridomas were isolated and screened according to established methods (Gavilondo JV. 1995. Monoclonal Antibodies: Theory and Practice, Elves Scientiae, Havana, Cuba).
- bactericidal antibody titer was expressed as the reciprocal of the highest antibody dilution evaluated, capable of killing 50% or more of the bacteria; two of the generated mAbs (3H2 / 64 and 7D2 / 15) had bactericidal titres greater than 1: 128 against the homologous strain B: 4: P1.19,15 and one (H8 / 92) greater than 1:80. They also had titers greater than 1: 64 against heterologous strains B: 15: P1.7,16 and C: 2a: P1.5.
- a SPOTScan type assay was performed. A series of overlapping peptides covering the protein sequence were synthesized on a cellulose support and the membrane was incubated with a mixture of sera diluted 1: 100. The antigen-antibody reaction was detected by incubation with an alkaline murine-alkaline phosphatase anti-lnmunoglobulin G conjugate, followed by the addition of a solution containing the Bromo-Chloro-Indolyl-Phosphate substrate. Several common antigenic regions present in the protein were observed, regardless of the preparation that was used in immunization. However, it was noted that in the groups immunized with protein adjuvant with Freund's Adjuvant a much broader recognition pattern was obtained.
- NMB1125 protein as a carrier of a peptide.
- a synthetic peptide of 15 amino acid residues was conjugated thereto, derived from the V3 region of the gp120 protein of HIV-1, JY1 isolation. The conjugation was performed by the glutaraldehyde method.
- the free JY1 peptide, the recombinant protein NMB1125 and the conjugate JY1-NMB1125 was administered to adult mice in a 3 dose scheme, where the immunogens were emulsified with Freund's Adjuvant.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/580,508 US7691971B2 (en) | 2003-12-03 | 2004-12-02 | Protein NMB1125 and use thereof in pharmaceutical formulations |
CA002547317A CA2547317A1 (en) | 2003-12-03 | 2004-12-02 | Protein nmb1125 and use thereof in pharmaceutical formulations |
EP04802607A EP1693378B9 (en) | 2003-12-03 | 2004-12-02 | Protein nmb1125 and use thereof in pharmaceutical formulations |
BRPI0417309-0A BRPI0417309A (pt) | 2003-12-03 | 2004-12-02 | proteìna nmb1125 e seu uso em formulações farmacêuticas |
DE602004023419T DE602004023419D1 (de) | 2003-12-03 | 2004-12-02 | Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen |
AU2004294376A AU2004294376A1 (en) | 2003-12-03 | 2004-12-02 | Protein NMB1125 and use thereof in pharmaceutical formulations |
AT04802607T ATE444305T1 (de) | 2003-12-03 | 2004-12-02 | Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen |
NZ547520A NZ547520A (en) | 2003-12-03 | 2004-12-02 | Protein NMB1125 and use thereof in pharmaceutical formulations |
PL04802607T PL1693378T3 (pl) | 2003-12-03 | 2004-12-02 | Białko NMB1125 i jego zastosowanie w kompozycjach farmaceutycznych |
NO20063020A NO20063020L (no) | 2003-12-03 | 2006-06-28 | Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20030285A CU23237A1 (es) | 2003-12-03 | 2003-12-03 | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
CUCU2003/0285 | 2003-12-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005054281A2 true WO2005054281A2 (es) | 2005-06-16 |
WO2005054281A3 WO2005054281A3 (es) | 2005-08-04 |
Family
ID=40091628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2004/000015 WO2005054281A2 (es) | 2003-12-03 | 2004-12-02 | Proteína nmb1125 y su uso en formulaciones farmaceuticas |
Country Status (18)
Country | Link |
---|---|
US (1) | US7691971B2 (es) |
EP (1) | EP1693378B9 (es) |
KR (1) | KR20060123759A (es) |
CN (1) | CN1890260A (es) |
AR (1) | AR047263A1 (es) |
AT (1) | ATE444305T1 (es) |
AU (1) | AU2004294376A1 (es) |
BR (1) | BRPI0417309A (es) |
CA (1) | CA2547317A1 (es) |
CU (1) | CU23237A1 (es) |
DE (1) | DE602004023419D1 (es) |
ES (1) | ES2334138T3 (es) |
NO (1) | NO20063020L (es) |
NZ (1) | NZ547520A (es) |
PL (1) | PL1693378T3 (es) |
RU (1) | RU2336900C2 (es) |
WO (1) | WO2005054281A2 (es) |
ZA (1) | ZA200604556B (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
ES2304065T3 (es) * | 1998-05-01 | 2008-09-01 | Novartis Vaccines And Diagnostics, Inc. | Antigenos y composiciones de neisseria meningitidis. |
BR0010361A (pt) * | 1999-04-30 | 2003-06-10 | Chiron Corp | Seq ências genÈmicas de neisseria e uso destas |
-
2003
- 2003-12-03 CU CU20030285A patent/CU23237A1/es unknown
-
2004
- 2004-12-01 AR ARP040104481A patent/AR047263A1/es unknown
- 2004-12-02 KR KR1020067010712A patent/KR20060123759A/ko not_active Application Discontinuation
- 2004-12-02 AU AU2004294376A patent/AU2004294376A1/en not_active Abandoned
- 2004-12-02 RU RU2006123434/13A patent/RU2336900C2/ru not_active IP Right Cessation
- 2004-12-02 CA CA002547317A patent/CA2547317A1/en not_active Abandoned
- 2004-12-02 US US10/580,508 patent/US7691971B2/en not_active Expired - Fee Related
- 2004-12-02 DE DE602004023419T patent/DE602004023419D1/de active Active
- 2004-12-02 ES ES04802607T patent/ES2334138T3/es active Active
- 2004-12-02 EP EP04802607A patent/EP1693378B9/en active Active
- 2004-12-02 AT AT04802607T patent/ATE444305T1/de not_active IP Right Cessation
- 2004-12-02 WO PCT/CU2004/000015 patent/WO2005054281A2/es active Application Filing
- 2004-12-02 BR BRPI0417309-0A patent/BRPI0417309A/pt not_active IP Right Cessation
- 2004-12-02 PL PL04802607T patent/PL1693378T3/pl unknown
- 2004-12-02 CN CNA2004800358779A patent/CN1890260A/zh active Pending
- 2004-12-02 NZ NZ547520A patent/NZ547520A/xx unknown
-
2006
- 2006-06-02 ZA ZA200604556A patent/ZA200604556B/xx unknown
- 2006-06-28 NO NO20063020A patent/NO20063020L/no not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
GIULIANI MM ET AL., PROCEEDINGS 12TH IPNC, 2000, pages 22 |
PIZZA M ET AL.: "Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing", SCIENCE, vol. 287, no. 5459, 2000, pages 1816 - 20 |
SANTINI L. ET AL., PROCEEDINGS 12TH IPNC., 2000, pages 25 |
Also Published As
Publication number | Publication date |
---|---|
RU2006123434A (ru) | 2008-01-10 |
NO20063020L (no) | 2006-09-01 |
CN1890260A (zh) | 2007-01-03 |
DE602004023419D1 (de) | 2009-11-12 |
PL1693378T3 (pl) | 2010-03-31 |
BRPI0417309A (pt) | 2007-09-11 |
AU2004294376A1 (en) | 2005-06-16 |
KR20060123759A (ko) | 2006-12-04 |
ATE444305T1 (de) | 2009-10-15 |
RU2336900C2 (ru) | 2008-10-27 |
NZ547520A (en) | 2009-07-31 |
EP1693378A2 (en) | 2006-08-23 |
ZA200604556B (en) | 2007-03-28 |
WO2005054281A3 (es) | 2005-08-04 |
CU23237A1 (es) | 2007-09-26 |
AR047263A1 (es) | 2006-01-11 |
CA2547317A1 (en) | 2005-06-16 |
US7691971B2 (en) | 2010-04-06 |
ES2334138T3 (es) | 2010-03-05 |
US20070218000A1 (en) | 2007-09-20 |
EP1693378B9 (en) | 2010-05-19 |
EP1693378B1 (en) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200604492B (en) | Protein NMB0928 and use thereof in pharmaceutical formulations | |
WO2007112702A2 (es) | Composición farmacéutica que comprende la proteína nmb0938 | |
WO2007112703A2 (es) | Composición farmacéutica que comprende la proteína nmb0606 | |
WO2009000217A1 (es) | Composición farmacéutica que comprende la proteína nmb1796 | |
EP1977761A2 (en) | Pharmaceutical compositions containing protein nma0939 | |
ES2334138T3 (es) | Proteina nmb1125 y uso de la misma en formulaciones farmaceuticas. | |
WO2009056075A1 (es) | Composición farmacéutica que comprende la proteína nmb0873 | |
MXPA06006267A (es) | Proteina nmbo928 y su uso en formulaciones farmaceuticas | |
MXPA06006266A (es) | Proteina nmb1125 y su uso en formulaciones farmaceuticas | |
MX2008008580A (es) | Composiciones farmaceuticas que contienen la proteina nma0939 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480035877.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2547317 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004802607 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 547520 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067010712 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/006266 Country of ref document: MX Ref document number: 200604556 Country of ref document: ZA Ref document number: 2006/04556 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004294376 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3646/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006123434 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2004294376 Country of ref document: AU Date of ref document: 20041202 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004294376 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004802607 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007218000 Country of ref document: US Ref document number: 10580508 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067010712 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0417309 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10580508 Country of ref document: US |